Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes

Area of Science:

• Immunology
• Hematology
• Infectious Diseases

Background:

• Viral infections pose a significant fatal risk for primary immunodeficiency (PID) patients undergoing hematopoietic stem cell transplantation (HSCT).
• Virus-specific T lymphocytes (VSTs) offer a promising therapeutic strategy for preventing and treating post-HSCT viral infections.
• This study details the clinical application of VSTs across four centers for PID patients.

Purpose of the Study:

• To assess the safety and efficacy of VST therapy in managing viral infections among PID patients.
• To aggregate clinical data on VST use in a cohort of PID patients.
• To compare VST production, infusion protocols, and adverse reactions.

Main Methods:

• Retrospective review of PID patients who received VST therapy.
• Evaluation of transplantation details, viral infections, and concomitant pharmacotherapy.
• Analysis of VST production, infusion parameters, and adverse events.

Main Results:

• Thirty-six PID patients received 37 VST products, with 72% infected by common viruses (CMV, EBV, adenovirus, BK, HHV-6).
• 81% of patients achieved a partial or complete response to VST therapy, with a median response time of 28 days.
• Overall survival at six months post-therapy was 80%, with manageable graft-versus-host disease in four patients.

Conclusions:

• Virus-specific T lymphocytes (VSTs) are a safe and effective treatment for viral infections in PID patients.
• VSTs can be derived from either stem cell donors or third-party donors.
• VST therapy demonstrates significant potential in improving outcomes for PID patients post-HSCT.